The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
Treatment of thrombotic complications in patients with MPN
|
Thrombotic events represent the most significant complications in patients with MPN, with a primary treatment goal of reducing their frequency and reccurrence.1 In current clinical practice, patients with either a history of thrombosis or aged ≥60 years are classed as high thrombotic risk and managed with cytoreductive treatment.1 More precise thrombotic risk evaluation may be feasible using other factors, such as the presence of a high (>1%) JAK2V617F allele burden.1
|
| Key learnings |
| Cytoreductive and anti-thrombotic agents are complementary for thrombotic risk reduction. Long-term anti-thrombotic strategies should be tailored to the initial thrombosis type, MPN subtype, and bleeding risk. |
| Antiplatelet therapy or revascularization may be required, with indefinite low-dose aspirin recommended following initial therapy after some thrombotic events. |
| Regular re-evaluation of the risk/benefit balance of continued antithrombotic treatment in MPN patients treated with anticoagulants is important for improving patient outcomes. |
| Patients with MPN and thrombosis should be cared for in multidisciplinary settings to ensure the provision of optimal individualized treatment strategies. |
Abbreviations: MPN, myeloproliferative neoplasms; SVT, splanchnic vein thrombosis.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
On average, how many patients with myelofibrosis do you see in a month?
